{"organizations": [], "uuid": "6dbacaa61ee5e901d1aae40badeb5106a3d8af64", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-aquinox-and-astellas-announce-excl/brief-aquinox-and-astellas-announce-exclusive-licensing-agreement-for-rosiptor-in-asia-pacific-region-including-japan-idUSFWN1SG1QA", "country": "US", "domain_rank": 408, "title": "BRIEF-Aquinox And Astellas Announce Exclusive Licensing Agreement For Rosiptor In Asia-Pacific Region Including Japan", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-10T04:12:00.000+03:00", "replies_count": 0, "uuid": "6dbacaa61ee5e901d1aae40badeb5106a3d8af64"}, "author": "", "url": "https://www.reuters.com/article/brief-aquinox-and-astellas-announce-excl/brief-aquinox-and-astellas-announce-exclusive-licensing-agreement-for-rosiptor-in-asia-pacific-region-including-japan-idUSFWN1SG1QA", "ord_in_thread": 0, "title": "BRIEF-Aquinox And Astellas Announce Exclusive Licensing Agreement For Rosiptor In Asia-Pacific Region Including Japan", "locations": [], "entities": {"persons": [{"name": "astellas", "sentiment": "none"}], "locations": [{"name": "asia-pacific", "sentiment": "none"}, {"name": "japan", "sentiment": "none"}, {"name": "japan", "sentiment": "none"}], "organizations": [{"name": "rosiptor in asia-pacific region including japan reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "astellas pharma inc", "sentiment": "none"}, {"name": "apac", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 9 (Reuters) - Astellas Pharma Inc:\n* AQUINOX AND ASTELLAS ANNOUNCE EXCLUSIVE LICENSING AGREEMENT FOR ROSIPTOR IN ASIA-PACIFIC REGION INCLUDING JAPAN\n* AQUINOX PHARMACEUTICALS SAYS AQUINOX TO RECEIVE $25 MILLION IN UPFRONT PAYMENT, POTENTIALLY OVER $100 MILLION IN ADDITIONAL MILESTONE PAYMENTS AND ROYALTIES\n* AQUINOX- ASTELLAS WILL HAVE EXCLUSIVE RIGHT TO RESEARCH, DEVELOP, COMMERCIALIZE ROSIPTOR FOR ALL HUMAN DISEASES AND CONDITIONS IN JAPAN, OTHER APAC COUNTRIES Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-05-10T04:12:00.000+03:00", "crawled": "2018-05-10T04:28:48.027+03:00", "highlightTitle": ""}